Is it safe to use metoclopramide (Reglan) together with lorazepam (Ativan)?

Compatibility of Reglan and Ativan

Metoclopramide (Reglan) and lorazepam (Ativan) can be used together safely and are frequently combined in clinical practice, particularly for managing chemotherapy-induced nausea and vomiting, though caution is warranted regarding additive sedation and CNS depression.

Evidence for Combined Use

The combination of metoclopramide and lorazepam has substantial clinical evidence supporting its safety and efficacy:

• Multiple randomized trials demonstrate successful concurrent use for antiemetic therapy. Studies show that metoclopramide plus lorazepam combinations effectively control cisplatin-induced emesis, with one trial using metoclopramide (2 mg/kg IV) with lorazepam (2 mg/m² IV) showing superior antiemetic control compared to metoclopramide alone 1.

• Guideline support exists for this combination. The 2000 Mayo Clinic antiemetic guidelines specifically recommend lorazepam (1 mg PO every 1-2 hours as needed) alongside metoclopramide (40 mg BID) for grade 4 emetogenic chemotherapy 2. The 2002 migraine guidelines list metoclopramide (10 mg IV or orally) as adjunctive therapy without contraindications to benzodiazepine co-administration 3.

• Research demonstrates enhanced efficacy when combined. A 1991 study found that high-dose metoclopramide plus lorazepam (2.5 mg × 4 PO) was safe and significantly superior to metoclopramide alone, though severe sedation occurred in some patients 4. Another 1991 trial achieved 100% vomiting control (76.1% complete response) with metoclopramide plus oral lorazepam (1 mg/day) versus only 55% with metoclopramide alone 5.

Critical Safety Considerations

Additive CNS Depression

The primary concern is enhanced sedation and respiratory depression when combining these medications:

• Benzodiazepines with antipsychotics carry specific warnings. The 2018 ESMO delirium guidelines caution that combining benzodiazepines with antipsychotics (including metoclopramide, a dopamine antagonist) increases risk of oversedation and respiratory depression 6. Lower doses should be used when co-administered (e.g., 0.5-1 mg lorazepam instead of standard doses).

• The Ativan FDA label explicitly warns about CNS depression when combined with other CNS depressants, stating that lorazepam produces additive depression when administered with phenothiazines and other antidepressants 7. While metoclopramide isn't specifically listed, it shares dopamine antagonist properties with phenothiazines.

• Clinical trials document significant sedation. Studies report sedation in 88% of patients receiving lorazepam combinations versus 43% with metoclopramide alone 1. One trial noted severe sedation in 6 patients receiving high-dose metoclopramide plus lorazepam, recommending individual dose adjustment 4.

Specific Populations Requiring Caution

Elderly patients are at higher risk:

• Use lower lorazepam doses (0.25-0.5 mg) when co-administered with antipsychotics 6
• Patients over 50 may experience more profound and prolonged sedation 7

Patients with respiratory compromise (COPD, pulmonary insufficiency):

• Reduce lorazepam doses significantly when combining with dopamine antagonists 6
• Monitor closely for respiratory depression

Pregnant patients:

• Both medications are used in pregnancy for hyperemesis gravidarum 8
• Metoclopramide shows no increased congenital defect risk
• Late pregnancy use of lorazepam can cause neonatal sedation and withdrawal 7

Rare but Serious Interactions

Serotonin syndrome risk: One case report documents metoclopramide-induced serotonin syndrome in a patient taking mirtazapine, successfully treated with lorazepam and cyproheptadine 9. This suggests lorazepam may actually be therapeutic in this context, though the combination requires monitoring in patients on serotonergic agents.

QTc prolongation: While metoclopramide can prolong QTc interval when combined with other QT-prolonging drugs 10, lorazepam does not share this risk.

Practical Dosing Algorithm

For antiemetic use:

1. Start with reduced doses: metoclopramide 10 mg + lorazepam 0.5-1 mg
2. Monitor for excessive sedation for 2-4 hours after first dose
3. If tolerated, may increase lorazepam to 1-2 mg as needed
4. Avoid exceeding lorazepam 2 mg when combined with metoclopramide
5. Limit use to avoid tardive dyskinesia (metoclopramide ≤12 weeks) 11

For elderly/frail patients:

• Metoclopramide 5-10 mg + lorazepam 0.25-0.5 mg
• Extended monitoring period (4-6 hours)

Red flags requiring immediate discontinuation:

• Respiratory rate <10/minute
• Inability to arouse patient
• Dystonic reactions (more common with metoclopramide)
• Paradoxical agitation

Common Pitfalls to Avoid

1. Don't assume standard benzodiazepine doses are safe when adding metoclopramide—reduce lorazepam by 50% initially
2. Don't combine with other CNS depressants (opioids, alcohol, other sedatives) without further dose reduction
3. Don't use long-term—metoclopramide carries black box warning for tardive dyskinesia beyond 12 weeks 11
4. Don't ignore excessive sedation—this is the most common adverse effect requiring dose adjustment 4, 1, 12

The combination is clinically established and generally safe when dosed appropriately with attention to additive sedation, particularly in vulnerable populations.